Peptides DB
Research-centric peptide and protocol reference hub
Study 19 of 32PE 22-28 literaturePregnancy hypertension · Observational2023

Antenatal risk stratification for preeclampsia with sFlt-1/PlGF ratio: Which is the best time to test?

The sFlt-1/PlGF ratio of 38 or more at 20-22 weeks can predict preeclampsia or adverse outcomes in high-risk pregnant women.

Read at Pregnancy hypertensionAdd to compare

Where it sits

this study against the rest of the pe 22-28 corpus
2
Preclinical
28
Observational · this one
0
Open-label
1
Randomised
1
Reviews

Summary and findings

The study measured the predictive value of the sFlt-1/PlGF ratio for antenatal risk stratification of women at high risk of preeclampsia. The testing was conducted at 20-22, 28-30, and 34-36 weeks of gestation. The results indicated that a ratio of 38 or more at 20-22 weeks was associated with adverse outcomes.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
The sFlt-1/PlGF ratio of 38 or more at 20-22 weeks resulted in either PE or adverse fetal outcome in all cases.2023

Abstract

The authors’ words, as Pregnancy hypertension supplied them

<h4>Objective</h4>To find out the predictive value of sFlt-1/PlGF ratio for antenatal risk stratification (ARS) of women at high risk of preeclampsia (PE).<h4>Methods</h4>Antenatal women at high risk of PE underwent sFlt-1/PlGF ratio at 20-22, 28-30 and 34-36 weeks and were followed till delivery. Those who developed PE were cases those who had normal outcome were controls, the cases and controls were compared.<h4>Results</h4>Hypertension in pregnancy was seen in 116/287 (40.4 %), 46/287(16.0 %) had PE and 21(7.3 %) had early onset PE. Mean arterial pressure at 20-22 weeks was the high in those who developed early onset PE (109.08 ± 9.74 mmHg). The sFlt-1/PlGF ratio of 38 or more at 20-22 weeks resulted in either PE or adverse fetal outcome in all cases. Whereas, the ratio of less than 38 ruled out PE in all cases up to 29 + 6 weeks. At 28-30 weeks, the ratio less than 38 predicted no PE up to 34 weeks and no complication up to 29<sup>+</sup>6 weeks. The sensitivity for the detection at later gestation further decreased as the gestation advanced however the specificity was above 98 % at all gestations. The positive predictive value of the test increased with the advancing gestation, the negative predictive value was 93 % or higher at all gestations.<h4>Conclusion</h4>The usefulness of sFlt-1/PlGF ratio ≥38 for risk stratification was validated in the study, the testing at 28-30 weeks appeared to be the best time to test for PE prediction in high risk women.

Background

Not reported in abstract.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Limitations

Not reported in abstract.

Elsewhere in the PE 22-28 corpus

CShortened Spadin Analogs Display Better TREK-1 Inhibition, <i>In Vivo</i> Stability and Antidepressant Activity.Frontiers in pharmacology · 2017 · IC50 of PE 22-28 was 0.12 nM vs. 40-60 nM for spadin.AnimalCN-terminal fusion length: The key to reliable and context-preserving regulatory sequence characterization.Synthetic and systems biotechnology · 2026 · mean R² > 0.75In vitroCEnhancing pectin degradation and improving nutritional accessibility in potato pulp through co-fermentation: From molecular structure to nutrient release.Food microbiology · 2026 · Pectin degradation reached 29.26 ± 0.41% under optimized conditions.AnimalCDiscovery of an Isothiazolinone-Containing Antitubercular Natural Product Levesquamide.The Journal of organic chemistry · 2020 · MIC of 9.65 μM against Mycobacterium tuberculosis H37Rv in microplate alamarBlue assay.In vitroCLymph node-targeted Nanovaccine Reshapes the Tumor Microenvironment to Suppress PDAC Progression and Metastasisbiorxiv-preprint · 2026 · Not reported in abstract.AnimalCTGF-β, but not IL-4, polarized macrophages induce fibrotic responses in lung fibroblastsbiorxiv-preprint · 2026 · Not reported in abstract.In vitro